GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TRACON Pharmaceuticals Inc (OTCPK:TCON) » Definitions » Shiller PE Ratio

TCON (TRACON Pharmaceuticals) Shiller PE Ratio : (As of Apr. 14, 2025)


View and export this data going back to 2015. Start your Free Trial

What is TRACON Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


TRACON Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for TRACON Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TRACON Pharmaceuticals Shiller PE Ratio Chart

TRACON Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TRACON Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TRACON Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, TRACON Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TRACON Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TRACON Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where TRACON Pharmaceuticals's Shiller PE Ratio falls into.


;
;

TRACON Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

TRACON Pharmaceuticals's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, TRACON Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.94/132.5538*132.5538
=-0.940

Current CPI (Jun. 2024) = 132.5538.

TRACON Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201409 -81.032 100.428 -106.953
201412 -44.150 99.070 -59.072
201503 -100.000 99.621 -133.058
201506 -48.000 100.684 -63.194
201509 -106.000 100.392 -139.959
201512 -182.000 99.792 -241.750
201603 -108.000 100.470 -142.488
201606 -136.000 101.688 -177.280
201609 -96.000 101.861 -124.927
201612 -90.000 101.863 -117.117
201703 -88.000 102.862 -113.402
201706 -80.000 103.349 -102.607
201709 14.000 104.136 17.821
201712 -74.000 104.011 -94.307
201803 -92.000 105.290 -115.823
201806 -66.000 106.317 -82.288
201809 -60.000 106.507 -74.673
201812 -52.000 105.998 -65.028
201903 -48.200 107.251 -59.572
201906 -42.200 108.070 -51.761
201909 -34.800 108.329 -42.582
201912 -25.000 108.420 -30.565
202003 -15.600 108.902 -18.988
202006 -14.000 108.767 -17.062
202009 -7.600 109.815 -9.174
202012 -5.570 109.897 -6.718
202103 -6.600 111.754 -7.828
202106 -11.600 114.631 -13.414
202109 -7.600 115.734 -8.704
202112 -8.000 117.630 -9.015
202203 -9.600 121.301 -10.491
202206 -6.200 125.017 -6.574
202209 -6.000 125.227 -6.351
202212 -6.200 125.222 -6.563
202303 -135.200 127.348 -140.727
202306 -3.940 128.729 -4.057
202309 5.800 129.860 5.920
202312 0.400 129.419 0.410
202403 -26.600 131.776 -26.757
202406 -0.940 132.554 -0.940

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TRACON Pharmaceuticals  (OTCPK:TCON) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


TRACON Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of TRACON Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TRACON Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.
Executives
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Charles Theuer director, officer: President and CEO C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Bonne J. Adams officer: Chief Operating Officer C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Scott B. Brown officer: Chief Accounting Officer (PAO) C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
William R Larue director C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122
Carol C. Lam director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122
Saundra L Pelletier director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Johnson-pratt director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Ikarian Healthcare Master Fund, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Mark C Wiggins officer: Chief Business Officer 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Neil Shahrestani 10 percent owner, other: Member of 10% Group 12806 WINDING CREEK DRIVE, FRISCO TX 75035
Ikarian Healthcare Fund Gp, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Chart Westcott Living Trust 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Ikarian Capital, Llc 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Puissance Cross-border Opportunities V Llc 10 percent owner 950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022